{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:58:26Z","timestamp":1790132306314,"version":"4.0.1"},"reference-count":29,"publisher":"The Endocrine Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"DOI":"10.1210\/jc.2018-02461","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T08:18:08Z","timestamp":1547021888000},"page":"1929-1936","source":"Crossref","is-referenced-by-count":75,"title":["Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas"],"prefix":"10.1210","volume":"104","author":[{"given":"Dongyun","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S","family":"Way","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareninov","family":"Sergey","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin","family":"Bergsneider","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilene B","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H","family":"Yong","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3865-0810","authenticated-orcid":false,"given":"Anthony P","family":"Heaney","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California"},{"name":"Department of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,1,8]]},"reference":[{"issue":"5","key":"2019041614024859700_B1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr Rev"},{"issue":"2","key":"2019041614024859700_B2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2019041614024859700_B3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1530\/EJE-12-0236","article-title":"Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients","volume":"167","author":"Vroonen","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2019041614024859700_B4","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1530\/EJE-11-1000","article-title":"Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients","volume":"166","author":"Primeau","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"2019041614024859700_B5","doi-asserted-by":"crossref","first-page":"587893","DOI":"10.1155\/2015\/587893","article-title":"Temozolomide therapy for aggressive pituitary tumors: results in a small series of patients from Argentina","volume":"2015","author":"Bruno","year":"2015","journal-title":"Int J Endocrinol"},{"issue":"6","key":"2019041614024859700_B6","first-page":"e658","article-title":"Treatment of aggressive prolactin-secreting pituitary adenomas with adjuvant temozolomide chemotherapy: a review","volume":"8","author":"Moisi","year":"2016","journal-title":"Cureus"},{"issue":"4","key":"2019041614024859700_B7","doi-asserted-by":"crossref","first-page":"R331","DOI":"10.1530\/ERC-14-0188","article-title":"The PI3K\/AKT\/mTOR pathway in the pathophysiology and treatment of pituitary adenomas","volume":"21","author":"Monsalves","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2019041614024859700_B8","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and treatment of pituitary adenomas: a review","volume":"317","author":"Molitch","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"2019041614024859700_B9","first-page":"1012","article-title":"From resistant to aggressive and malignant prolactinomas: a translational approach","volume":"1","author":"Jaffrain-Rea","year":"2014","journal-title":"J Endocr Disord"},{"issue":"3","key":"2019041614024859700_B10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11060-014-1413-6","article-title":"Management of aggressive pituitary adenomas and pituitary carcinomas","volume":"117","author":"Heaney","year":"2014","journal-title":"J Neurooncol"},{"key":"2019041614024859700_B11","author":"Raverot"},{"issue":"8","key":"2019041614024859700_B12","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism","volume":"7","author":"Engelman","year":"2006","journal-title":"Nat Rev Genet"},{"issue":"1","key":"2019041614024859700_B13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12022-012-9230-y","article-title":"mTOR is frequently active in GH-secreting pituitary adenomas without influencing their morphopathological features","volume":"24","author":"Sajjad","year":"2013","journal-title":"Endocr Pathol"},{"issue":"2","key":"2019041614024859700_B14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1677\/erc.1.00949","article-title":"Enhanced protein kinase B\/Akt signalling in pituitary tumours","volume":"12","author":"Mu\u015fat","year":"2005","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"2019041614024859700_B15","first-page":"3123","article-title":"Expression of the mTOR pathway regulators in human pituitary adenomas indicates the clinical course","volume":"33","author":"Jia","year":"2013","journal-title":"Anticancer Res"},{"issue":"9","key":"2019041614024859700_B16","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tcb.2015.06.002","article-title":"Regulation of mTORC1 by PI3K signaling","volume":"25","author":"Dibble","year":"2015","journal-title":"Trends Cell Biol"},{"issue":"11","key":"2019041614024859700_B17","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.bbamcr.2011.03.010","article-title":"Akt, FoxO and regulation of apoptosis","volume":"1813","author":"Zhang","year":"2011","journal-title":"Biochim Biophys Acta"},{"issue":"25","key":"2019041614024859700_B18","doi-asserted-by":"crossref","first-page":"8649","DOI":"10.1073\/pnas.0802533105","article-title":"Akt phosphorylation and nuclear phosphoinositide association mediate mRNA export and cell proliferation activities by ALY","volume":"105","author":"Okada","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2019041614024859700_B19","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ceb.2009.02.002","article-title":"PIKKing on PKB: regulation of PKB activity by phosphorylation","volume":"21","author":"Bozulic","year":"2009","journal-title":"Curr Opin Cell Biol"},{"issue":"7","key":"2019041614024859700_B20","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1517\/14740338.2015.1040388","article-title":"Everolimus and sirolimus in transplantation-related but different","volume":"14","author":"Klawitter","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"2019041614024859700_B21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1758834016675803","article-title":"Refractory carcinoid syndrome: a review of treatment options","volume":"9","author":"Riechelmann","year":"2017","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"2019041614024859700_B22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","article-title":"Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial","volume":"28","author":"Yao","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9808","key":"2019041614024859700_B23","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"2019041614024859700_B24","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1677\/ERC-08-0269","article-title":"Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro","volume":"16","author":"Gorshtein","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2019041614024859700_B25","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1210\/jc.2009-1641","article-title":"Effect of everolimus on cell viability in nonfunctioning pituitary adenomas","volume":"95","author":"Zatelli","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041614024859700_B26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/2152-7806.77029","article-title":"mTOR inhibition reduces cellular proliferation and sensitizes pituitary adenoma cells to ionizing radiation","volume":"2","author":"Sukumari-Ramesh","year":"2011","journal-title":"Surg Neurol Int"},{"issue":"2","key":"2019041614024859700_B27","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1158\/0008-5472.CAN-09-2951","article-title":"The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells","volume":"70","author":"Cerovac","year":"2010","journal-title":"Cancer Res"},{"issue":"1","key":"2019041614024859700_B28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11102-011-0341-0","article-title":"New targeted therapies in pituitary carcinoma resistant to temozolomide","volume":"15","author":"Jouanneau","year":"2012","journal-title":"Pituitary"},{"issue":"5","key":"2019041614024859700_B29","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1530\/EJE-12-1101","article-title":"Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia","volume":"168","author":"Bernard","year":"2013","journal-title":"Eur J Endocrinol"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/jc.2018-02461\/27386705\/jc.2018-02461.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/6\/1929\/28462670\/jc.2018-02461.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T14:03:24Z","timestamp":1555423404000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/104\/6\/1929\/5273783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,8]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,1,8]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2018-02461","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6]]},"published":{"date-parts":[[2019,1,8]]}}}